CEGX Expands in-house Expertise

Epigenetic technologies company Cambridge Epigenetix (CEGX) has appointed Professor Mark Dawson, MBBS (Hons), BMedSci, FRACP, FRCPA, PhD to its Scientific Board. Professor in the Sir Peter MacCallum Department of Oncology and Centre for Cancer Research at the University of Melbourne, he is the Program Head of Translational Haematology, Group Leader of the Cancer Epigenetics Laboratory and Consultant Haematologist in the Department of Haematology with research focused on epigenetic regulation in normal and malignant haematopoiesis. Professor Dawson helped to develop BET inhibitors, a novel epigenetic cancer therapy, which has entered early-phase clinical trials for patients with haematological cancers and has significant experience in studying the role of epigenetic proteins in the initiation and maintenance of a range of malignancies.

Towards the end of last year the company also appointed Hayden Jeffreys as Chief Operating Officer (COO), and Dr Joanne Mason as Vice President (VP) of Biomarker Discovery. With 20 years experience in clinical diagnostics specialising in the molecular diagnostic and blood bank , Hayden has expertise in leading and implementing organisation transformation to create stakeholder value and grow revenue by driving commercial operations and linking R&D output into commercially viable products.

Joanne sits on the MHRA Genomics for Diagnosis Forum, UK NEQAS for molecular genetics DNA extraction steering committee and Genomics England sequencing advisory board. As former Director of Sequencing and Sample Acquisition for Genomics England, she managed sample collection and sequencing for the 100,000 Genomes Project and has in-depth experience leading core facility translational research